This site is intended for Healthcare Professionals only.

Drugmaker Sandoz to pay $265m to settle US pricing case


Share post:

Swiss generic drugmaker Sandoz said on Thursday that it would pay $265 million (£209m) to settle a pricing antitrust case in the US.

Under the agreement, Sandoz is resolving all damages claims without admitting to any wrongdoing in the case brought in the US state of Pennsylvania.

“Under the terms of the agreement, Sandoz US will pay $265 million in exchange for a full release of all claims asserted against it in the direct purchaser class action by the settlement class members,” the company said in a statement, adding that the payment would be incorporated into 2023 results.

Sandoz became an independent company in October 2023, following the spinoff from Novartis.

“As a new public company, this settlement underscores the Sandoz commitment to integrity and sound governance, and is an encouraging step toward putting allegations of legacy conduct behind us”, it said in its statement.

In a separate case in 2020, Sandoz had agreed to pay $195m to avoid trial in the US on charges it conspired to fix prices of generic drugs.



Please enter your comment!
Please enter your name here

Current Issue March 2024

Related articles

Europe Sees Surge in Generic Medicines Withdrawals; UK Faces Doubling of Drug Shortages

Generic medicines for cancer and mental health on the Union List of Critical Medicines are disappearing, study reveals...

NHS to support newly-trained pharmacists with new £1.5 million investment

The new initiative is set to create highly-skilled placement opportunities in community pharmacies, GP surgeries, and care homes...

Professor Mahendra Patel joins UK Pharmacy Professional Leadership Advisory Board

The nine independent expert members of the UK Pharmacy Professional Leadership Advisory Board announced   Professor Mahendra Patel OBE,...

Silent suffering: 12k NHS staff reluctant to share mental health and well-being struggles

Latest UNISON survey underscores mental health absence affecting over 30 per cent of NHS staff including paramedics, and...